<PAGE>

                                          
                                    UNITED STATES
                         SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, DC 20549
                                          
                                     FORM 10-Q



(Mark One)
 
/ X /     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES 
-----     EXCHANGE ACT OF 1934.

For the quarterly period ended MARCH 31, 1998
                               --------------
 
/   /     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES 
-----     EXCHANGE ACT OF 1934.

For the transition period from ________________ to ______________

Commission file number 0-18006
                       -------


                          THE IMMUNE RESPONSE CORPORATION
               (Exact Name of Registrant as Specified in its Charter)


               DELAWARE                         33-0255679  
(State or Other Jurisdiction of    (IRS Employer Identification Number)
 Incorporation or Organization)


                       5935 DARWIN COURT, CARLSBAD, CA  92008
                      (Address of Principal Executive Offices)
                                     (Zip Code)
                                          
                                          
                              TELEPHONE (760) 431-7080
                (Registrant's Telephone Number, Including Area Code)
                                          


Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.      
Yes  X    No        
    ---      ---

Indicate the number of shares outstanding of each of the Issuer's classes of
common stock, as of the latest practicable date.

As of May 5, 1998, 22,868,512 shares of common stock were outstanding.

<PAGE>

                          THE IMMUNE RESPONSE CORPORATION
                                          
                                     FORM 10-Q
                                          
                                  QUARTERLY REPORT
                                          
                                          
                                 TABLE OF CONTENTS
                                          
                                                                           PAGE
                                            
                           PART I - FINANCIAL INFORMATION


Item 1.   Financial Statements

          Condensed Consolidated Balance Sheets                                3
          Condensed Consolidated Statements of Operations                      4
          Condensed Consolidated Statements of Cash Flows                      5
          Notes to Condensed Consolidated Financial Statements                 6


Item 2.   Management's Discussion and Analysis of Financial Condition 
          and Results of Operations                                            7


                            PART II - OTHER INFORMATION



Item 6.   Exhibits and Reports on Form 8-K                                    15


Signature                                                                     16

                                          2
<PAGE>


                                          
                                          
PART I.      FINANCIAL INFORMATION
ITEM 1.      FINANCIAL STATEMENTS



                          THE IMMUNE RESPONSE CORPORATION
                                          
                       CONDENSED CONSOLIDATED BALANCE SHEETS
                         (in thousands, except share data)


<TABLE>
<CAPTION>
                                                                            March 31,
                                                                               1998       December 31,
                                                                           (unaudited)        1997   
                                                                           ------------   -------------
<S>                                                                        <C>            <C>
Assets
Current Assets:                                                                      
    Cash and cash equivalents                                               $   2,553     $   4,872
    Marketable securities-available-for-sale                                   20,931        25,567
    Other current assets                                                          486           773
                                                                           ------------   -------------
            Total current assets                                               23,970        31,212


Property and equipment, net                                                     5,529         5,810
Deposits and other assets                                                         954           353
                                                                           ------------   -------------
                                                                            $  30,453     $  37,375
                                                                           ------------   -------------
                                                                           ------------   -------------


LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
    Accounts payable                                                        $   2,372     $   1,356
    Other accrued expenses                                                        851           917
                                                                           ------------   -------------
            Total current liabilities                                           3,223         2,273

Stockholders' equity:
    Preferred stock, 5,000,000 shares authorized; none issued                      --            --
    Common stock, $.0025 par value, 40,000,000 shares authorized,
        22,833,715 and 22,815,054 shares issued and outstanding at
        March 31, 1998 and December 31, 1997, respectively                         57            57
    Warrants                                                                    2,144         2,144
    Additional paid-in capital                                                186,441       186,374
    Cumulative comprehensive income                                                37            27
    Accumulated deficit                                                      (161,449)     (153,500)
                                                                           ------------   -------------
            Total stockholders' equity                                         27,230        35,102
                                                                           ------------   -------------
                                                                            $  30,453     $  37,375
                                                                           ------------   -------------
                                                                           ------------   -------------
</TABLE>
See accompanying notes.
 

                                         3


<PAGE>

                          THE IMMUNE RESPONSE CORPORATION
                                          
                  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                         (in thousands, except share data)
                                    (unaudited)


<TABLE>
<CAPTION>
                                                                        Three months ended March 31,
                                                                        -----------------------------
                                                                            1998            1997
                                                                        -------------   -------------
<S>                                                                     <C>             <C>
Contract research revenue                                                 $     1,000   $     1,000


Expenses:
    Research and development                                                    8,261         8,598
    General and administrative                                                    999           994
                                                                        -------------   -------------
                                                                                9,260         9,592

Other revenue:
    Investment income                                                             311           609
                                                                        -------------   -------------
Net loss                                                                  $    (7,949)  $    (7,983)
                                                                        -------------   -------------
                                                                        -------------   -------------
Net loss per share - basic and diluted                                    $     (0.35)  $     (0.39)
                                                                        -------------   -------------
                                                                        -------------   -------------
Weighted average number of shares
    outstanding                                                            22,824,397    20,259,837
                                                                        -------------   -------------
                                                                        -------------   -------------

</TABLE>

See accompanying notes.

                                         4

<PAGE>


                          THE IMMUNE RESPONSE CORPORATION
                                          
                  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                    (unaudited)


<TABLE>
<CAPTION>
                                                                        Three months ended March 31,
                                                                        -----------------------------
                                                                            1998            1997
                                                                        -------------   -------------
<S>                                                                     <C>             <C>
Operating activities:
    Net loss                                                            $      (7,949)  $    (7,983)
    Adjustments to reconcile net loss to net cash provided from
       (used by) operating activities:
           Depreciation and amortization                                          371           239
           Deferred rent expense                                                  (22)          (15)
           Changes in operating assets and liabilities:
               Other current assets                                               287            46
               Accounts payable                                                 1,016           150
               Accrued expenses                                                   (44)         (117)
                                                                        -------------   -------------
                    Net cash used by operating activities                      (6,341)       (7,680)


Investing activities:
    Purchase/sale of marketable securities, net                                 4,645         8,195
    Purchase of property and equipment                                            (89)         (678)
    Deposits and other assets                                                    (601)          (68)
                                                                        -------------   -------------
                    Net cash provided from investing activities                 3,955         7,449


Financing activities:
    Net proceeds from exercise of stock options                                    67           206
                                                                        -------------   -------------
                    Net cash provided from financing activities                    67           206
                                                                        -------------   -------------
Net decrease in cash and cash equivalents                                      (2,319)          (25)
Cash and cash equivalents at beginning of period                                4,872         3,785
                                                                        -------------   -------------
Cash and cash equivalents at end of period                              $       2,553   $     3,760
                                                                        -------------   -------------
                                                                        -------------   -------------

</TABLE>

See accompanying notes.
 

                                         5

<PAGE>


                          THE IMMUNE RESPONSE CORPORATION
                                          
                NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                          
                                   MARCH 31, 1998


1.   BASIS OF PRESENTATION
     The condensed consolidated financial statements of The Immune Response
     Corporation (the "Company") for the three months ended March 31, 1998 and
     1997 are unaudited.  These financial statements reflect all adjustments,
     consisting of only normal recurring adjustments which, in the opinion of
     management, are necessary to fairly present the consolidated financial
     position as of March 31, 1998, and the consolidated results of operations
     for the three months ended March 31, 1998 and 1997.  The results of
     operations for the three months ended March 31, 1998 are not necessarily
     indicative of the results to be expected for the year ended December 31,
     1998.  For more complete financial information, these financial
     statements, and the notes thereto, should be read in conjunction with the
     consolidated audited financial statements for the year ended December 31,
     1997 included in the Company's Form 10-K filed with the Securities and
     Exchange Commission.


2.   NET LOSS PER SHARE
     Net loss per share for the three months ended March 31, 1998 and 1997 is
     computed using the weighted average number of common shares outstanding
     during the period.  Outstanding stock options and warrants are not
     included in the calculation of earnings per share because as their effect
     would be  antidilutive.  Therefore, there is no difference between basic
     and diluted net loss per share. 


3.   COMPREHENSIVE INCOME
     In January 1998, the Company adopted Statement of Financial Accounting
     Standards ("FAS") No. 130, "Reporting Comprehensive Income."  The
     components of comprehensive income are as follows:

<TABLE>
<CAPTION>
                                                   Three Months Ended
                                              ------------------------------
                                              March 31,           March 31,
                                                 1998                1997 
                                              -----------         ----------
     <S>                                      <C>                 <C>
     Net loss                                  $ (7,949)           $ (7,983)
     Net unrealized gain (loss) on
       marketable securities                         10                (113)
                                              -----------          ---------
     Comprehensive loss                        $ (7,939)           $ (8,096)
                                              -----------          ---------
                                              -----------          ---------
</TABLE>

     All prior periods have been restated to reflect the adoption of this
     statement.

     
4.   SUBSEQUENT EVENT
     During April 1998, the Company sold 200 shares of its Series F Convertible
     Preferred Stock ("Series F Stock") in return for gross proceeds of $10
     million.  The Series F Stock is convertible into common stock initially at
     a conversion price of $14.07 per share of common stock.  If the Company's
     common stock does not trade at prices higher than $14.07 per share over a
     period of time, the conversion price will be adjusted downward on April 24,
     1999 (or sooner if the Company issues common stock at less than $14.07 per
     share) and quarterly thereafter.  The Series F Stock bears a dividend of
     7.5% per annum.  In general, the dividend is payable in shares of common
     stock.  The Company has agreed to file a registration statement with the
     Securities and Exchange Commission covering the resale of the common stock
     issuable upon conversion of the Series F Stock.  Further, the Company has
     the option for one year to sell up to $10 million more of the Series F
     Stock if certain conditions are met.  

                                               6

<PAGE>


ITEM 2.        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND
               RESULTS OF OPERATIONS


SUMMARY
The Immune Response Corporation (the "Company") is a biopharmaceutical 
company developing immune-based therapies to induce specific T cell responses 
for the treatment of HIV, autoimmune diseases and cancer.  The Company is 
conducting clinical trials for its immune-based therapies for HIV, rheumatoid 
arthritis, psoriasis, multiple sclerosis, colon cancer and brain cancer and 
preclinical studies for prostate cancer.  In addition, the Company is 
developing a targeted delivery technology for gene therapy which is designed 
to enable the intravenous injection of genes for delivery directly to the 
liver. The Company's gene therapy program is currently focused on diseases of 
the liver and is in preclinical studies for the treatment of hemophilia and 
hepatitis. The Company's strategy is to retain ownership of these proprietary 
technologies and to seek corporate collaborations or joint ventures for 
certain disease-specific applications.

This discussion contains forward-looking statements concerning the Company's 
operating results and timing of anticipated expenditures.  Such statements 
are subject to risks and uncertainties which could cause actual results to 
differ materially from those projected.  For a further description of 
potential risks and uncertainties involved related to the Company, this 
document should be read in conjunction with the Company's 1997 Form 10-K 
filed with the Securities and Exchange Commission.  These forward-looking 
statements speak only as of the date hereof.  The Company undertakes no 
obligation to publicly release the result of any revisions to these 
forward-looking statements which may be made to reflect events or 
circumstances after the date hereof or to reflect the occurrence of 
unanticipated events.

During April 1998, the Company sold 200 shares of its Series F Convertible 
Preferred Stock ("Series F Stock") in return for gross proceeds of $10 
million. The Series F Stock is convertible into common stock initially at a 
conversion price of $14.07 per share of common stock.  If the Company's 
common stock does not trade at prices higher than $14.07 per share over a 
period of time, the conversion price will be adjusted downward on April 24, 
1999 (or sooner if the Company issues common stock at less than $14.07 per 
share) and quarterly thereafter.  The Series F Stock bears a dividend of 7.5% 
per annum.  In general, the dividend is payable in shares of common stock.  
The Company has agreed to file a registration statement with the Securities 
and Exchange Commission covering the resale of the common stock issuable upon 
conversion of the Series F Stock.  Further, the Company has the option for 
one year to sell up to $10 million more of the Series F Stock if certain 
conditions are met.

The Company has not been profitable since inception and had an accumulated 
deficit of $161 million as of March 31, 1998.  To date, the Company has not 
recorded any revenues from the sale of products.  Revenues recorded through 
March 31,1998 were earned in connection with contract research and investment 
income.  There can be no assurance that the Company will be able to generate 
sufficient product revenue to become profitable at all or on a sustained 
basis.

RESULTS OF OPERATIONS
The Company had $1 million in contract research revenue during the quarters 
ended March 31, 1998 and 1997.  Contract research revenue was received from 
Bayer Corporation related to a research collaboration for a potential therapy 
for  hemophilia.  The Company has not received any revenue from the 
commercial sale of products and does not expect to derive revenue from the 
sale of products for the foreseeable future.

Investment income decreased to $310,000 for the quarter ended March 31, 1998, 
from $609,000 during the same period in 1997.  The decrease in investment 
income in 1998 compared to 1997, was due primarily to a decrease in the 
Company's cash position from the first quarter of 1997 compared to 1998.

Research and development expenditures of $8.3 million during the first 
quarter of 1998 decreased from $8.6 million during the same period in 1997.  
This decrease in costs from 1997 was due primarily to the initial costs 
incurred to enroll the final clinical trial sites related to the Phase III 
clinical endpoint trial for HIV infection using REMUNE during the first 
quarter of 1997.  The Company expects research and development 

                                          7

<PAGE>

expenditures to rise as it continues its Phase IIb rheumatoid arthritis 
clinical trial, expected to be completed by year-end 1998, and its Phase II 
psoriasis clinical trial, expected to be completed during the third quarter 
of 1998.  Research and development expenditures should also continue to rise 
in the foreseeable future due to expanding preclinical and clinical testing 
of the Company's proposed gene therapy and cancer treatments.  Research and 
development expenses related to advancing REMUNE are also expected to 
increase due to the continuance of the Company's ongoing large scale Phase 
III clinical endpoint trial with REMUNE and to pre-marketing activities as 
the Company approaches possible commercialization of REMUNE.  There can be no 
assurance that REMUNE will be successfully developed or commercialized.

General and administrative expenses for the first quarter of 1998 were 
$999,000 as compared to $994,000 for the same period in 1997. General and 
administrative expenses for the remainder of 1998 necessary to support the 
Company's expanded research and development activities are expected to remain 
consistent with first quarter levels.

For the quarter ended March 31, 1998, the Company's net loss was $7.9 
million, or $.35 per share, as compared to a net loss of $8.0 million, or 
$.39 per share, for the same period in 1997.  The change in the earnings per 
share in 1998 from 1997, despite comparable net loss results, was primarily 
due to the additional shares issued in a private stock offering in April 
1997. 

LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 1998, the Company had working capital of $21.6 million, 
including $23.5 million of cash, cash equivalents and marketable securities. 
This compares with working capital at December 31, 1997, of $28.9 million, 
including $30.4 million of cash, cash equivalents and marketable securities. 
The decrease in working capital was due to the costs of operating the 
business. In April 1998, the sale of 200 shares of Series F Stock resulted in 
net proceeds to the Company of approximately $9 million.

The Company will need to raise additional funds to conduct research and 
development, preclinical studies and clinical trials necessary to bring its 
potential products to market and establish manufacturing and marketing 
capabilities. The Company anticipates that in 1998, the REMUNE clinical 
trials will continue to represent a significant portion of the Company's 
overall expenditures.  The Company also anticipates that costs related to the 
development of REMUNE will continue to increase as the Company approaches 
possible commercialization.  The anticipated costs with respect to REMUNE 
will depend on many factors, including the results of interim analyses of the 
data from the Phase III clinical endpoint trial,  the potential for 
accelerated approval and certain other factors which will influence the 
Company's determination of the appropriate continued investment of the 
Company's financial resources in this program.  The Company's future capital 
requirements will depend on many factors, including continued scientific 
progress in its research and development programs, the scope and results of 
preclinical studies and clinical trials, the time and costs involved in 
obtaining regulatory approvals, the costs involved in filing, prosecuting and 
enforcing patent claims, competing technological and market developments, the 
cost of manufacturing scale-up, effective commercialization activities and 
arrangements and other factors not within the Company's control.  The Company 
intends to seek additional funding, in addition to the recently completed 
Series F Stock transaction, through public or private financings, 
arrangements with corporate collaborators or other sources.  If funds are 
acquired through collaborations, the Company will likely be required to 
relinquish some or all rights to products that the Company may have otherwise 
developed itself.  Adequate funds may not be available when needed or on 
terms acceptable to the Company.  Insufficient funds may require the Company 
to scale back or eliminate some or all of its research and development 
programs or license to third parties products or technologies that the 
Company would otherwise seek to develop itself.  The Company believes that 
its existing resources, the resources received from the Series F Stock 
transaction completed in April 1998, and interest thereon, will enable the 
Company to maintain its current and planned operations beyond 1998.

YEAR 2000
The Company is conducting a comprehensive review of its computer systems to 
identify the systems that could be affected by the "Year 2000" issue and has 
created a plan to resolve the issue.  The Year 2000 problem is the result of 
computer programs being written using two digits rather than four digits to 
define the applicable year.  Any of the Company's programs that have 
time-sensitive software may recognize a date using "00" as the year 1900 
rather than the year 2000.  This could result in a major system failure or

                                       8

<PAGE>

miscalculations.  The Company presently believes that the Year 2000 problem 
will not pose significant operational problems for the Company's computer 
systems.

CERTAIN RISK FACTORS (For a discussion of additional Risk Factors applicable 
to the Company, see the Company's Annual Report on Form 10-K for the year 
ended December 31, 1997.)

UNCERTAINTY OF PRODUCT DEVELOPMENT AND CLINICAL TESTING.   The Company has 
not completed the development of any products and there can be no assurance 
any products will be successfully developed.  The Company has been in 
existence since 1986, and to date only six of its product candidates have 
entered clinical trials.  The Company's potential immune-based therapies for 
HIV, autoimmune disease, cancer and gene therapy products currently under 
development will require significant additional research and development 
efforts and regulatory approvals prior to potential commercialization.  To 
achieve profitable operations, the Company must successfully develop, 
manufacture, introduce and market products.  There can be no assurance that 
any of the Company's potential products will prove to be safe and effective 
in clinical trials, that Food and Drug Administration ("FDA") or other 
regulatory approvals will be obtained or that such products will achieve 
market acceptance. 

The Company's potential HIV immune-based therapy, REMUNE, is in a Phase III 
clinical endpoint trial designed to provide evidence of efficacy based on 
clinical endpoints.  There can be no assurance that the results of such 
clinical trial will demonstrate that REMUNE is safe and efficacious or, that 
even if the results of the clinical trial are considered successful by the 
Company, that the Food and Drug Administration ("FDA") will not require the 
Company to conduct additional large scale clinical trials with REMUNE before 
the FDA will consider approving REMUNE for commercial sale.  Failure to 
successfully complete the Phase III clinical endpoint trial in a timely 
fashion and a failure to obtain FDA approval of REMUNE will materially and 
adversely affect the Company.  There can be no assurance that the results of 
the Phase III trial will be consistent with Phase II results.  Even if 
results of the Phase III trial are consistent with the Phase II trial 
results, there can be no assurance that the FDA would approve REMUNE for 
marketing.  In addition, REMUNE is being tested in a Phase II clinical trial 
in Thailand, in a pediatric Phase I clinical trial in the United States and 
in combination trials with approved HIV therapies in the United States, 
Spain, Switzerland and Great Britain.  Failure of these trials to demonstrate 
the safety and effectiveness of REMUNE could have a material adverse effect 
on the regulatory approval process for this potential product.  The Company's 
other potential immune-based therapies and gene therapy technologies are at a 
much earlier stage of development than REMUNE.  The Company's gene therapy 
technology and certain of its technologies for the treatment of cancer have 
not yet been tested in humans and there can be no assurance that human 
testing of potential products based on such technologies will be permitted by 
regulatory authorities or, that even if human testing is permitted, that 
products based on such technologies will be developed and shown to be safe or 
efficacious.  Potential immune-based therapies based on certain of the 
Company's autoimmune technology and certain of its cancer technologies are at 
an early stage of clinical testing and there can be no assurance that such 
products will be shown to be safe, efficacious or receive regulatory approval.

There can be no assurance that the results of the Company's preclinical 
studies and clinical trials will be indicative of future clinical trial 
results.  A commitment of substantial resources to conduct time-consuming 
research, preclinical studies and clinical trials, including the REMUNE Phase 
III clinical endpoint trial will be required if the Company is to develop any 
products. Delays in planned patient enrollment in the Company's current 
clinical trials or future clinical trials may result in increased costs, 
program delays or both. There can be no assurance that any of the Company's 
potential products will prove to be safe and effective in clinical trials, 
that FDA or other regulatory approvals will be obtained or that such products 
will achieve market acceptance. Any products resulting from these programs 
are not expected to be successfully developed or commercially available for a 
number of years, if at all.

There can be no assurance that unacceptable toxicities or side effects will 
not occur at any time in the course of human clinical trials or, if any 
products are successfully developed and approved for marketing, during 
commercial use of the Company's products.  The appearance of any such 
unacceptable toxicities or side effects could interrupt, limit, delay or 
abort the development of any of the Company's products or, if previously 
approved, necessitate their withdrawal from the market.  Furthermore, there 
can be no assurance that disease resistance will not limit the efficacy of 
potential products.

                                        9

<PAGE>

ADDITIONAL FINANCING REQUIREMENTS AND ACCESS TO CAPITAL. The Company will 
need to raise additional funds to conduct research and development, 
preclinical studies and clinical trials necessary to bring its potential 
products to market and establish manufacturing and marketing capabilities. 
The Company anticipates that in 1998, the REMUNE clinical trials will 
continue to represent a significant portion of the Company's overall 
expenditures.  The Company also anticipates that costs related to the 
development of REMUNE will continue to increase as the Company approaches 
possible commercialization.  The anticipated costs with respect to REMUNE 
will depend on many factors, including the results of interim analyses of the 
data from the Phase III clinical endpoint trial, the potential for 
accelerated approval and certain other factors which will influence the 
Company's determination of the appropriate continued investment of the 
Company's financial resources in this program.  The Company's future capital 
requirements will depend on many factors, including continued scientific 
progress in its research and development programs, the scope and results of 
preclinical studies and clinical trials, the time and costs involved in 
obtaining regulatory approvals, the costs involved in filing, prosecuting and 
enforcing patent claims, competing technological and market developments, the 
cost of manufacturing scale-up, effective commercialization activities and 
arrangements and other factors not within the Company's control.  The Company 
intends to seek additional funding, in addition to the recently completed 
Series F Stock transaction, through public or private financings, 
arrangements with corporate collaborators or other sources.  If funds are 
acquired through collaborations, the Company will likely be required to 
relinquish some or all rights to products that the Company may have otherwise 
developed itself. Adequate funds may not be available when needed or on terms 
acceptable to the Company.  Insufficient funds may require the Company to 
scale back or eliminate some or all of its research and development programs 
or license to third parties products or technologies that the Company would 
otherwise seek to develop itself.  The Company believes that its existing 
resources, the resources received from the Series F Stock transaction 
completed in April 1998, and interest thereon, will enable the Company to 
maintain its current and planned operations beyond 1998.

PATENTS AND PROPRIETARY TECHNOLOGY.  The Company has filed, or participated 
as licensee, in the filing of a number of patent applications in the United 
States and many international countries.  The Company files applications as 
appropriate for patents covering its products and processes.  The Company has 
been issued patents, or has licensed patents, covering certain aspects of its 
proposed immune-based therapies for HIV, autoimmune disease, cancer and gene 
therapy technologies.  The Company's success may depend in part on its 
ability to obtain patent protection for its products and processes.  The 
Company is aware that a group working with Connetics Corporation has received 
a United States patent related to autoimmune disease research that covers 
technology similar to that used by the Company    

There can be no assurance that the Company will be able to negotiate any 
necessary cross licenses, and if not successful, failure to do so could have 
a negative impact on the Company.   There can be no assurance that the 
Company's patent applications will be issued as patents or that any of its 
issued patents, or any patent that may be issued in the future, will provide 
the Company with adequate protection for the covered products, processes or 
technology.

The patent positions of biotechnology and pharmaceutical companies can be 
highly uncertain, and involve complex legal and factual questions.  
Therefore, the breadth of claims allowed in biotechnology and pharmaceutical 
patents cannot be predicted.  The Company also relies upon unpatented trade 
secrets and know how, and no assurance can be given that others will not 
independently develop substantially equivalent trade secrets or know how.  In 
addition, whether or not the Company's patents are issued, or issued with 
limited coverage, others may receive patents which contain claims applicable 
to the Company's product.  There can be no assurance that any of the 
Company's patents, or any patents issued to the Company in the future, will 
afford meaningful protection against competitors.  Defending any such patent 
could be costly to the Company, and there can be no assurance that the patent 
would be held valid by a court of competent jurisdiction.

The Company also relies on protecting its proprietary technology in part 
through confidentiality agreements with its corporate collaborators, 
employees, consultants and certain contractors.  There can be no assurance 
that these agreements will not be breached, that the Company will have 
adequate remedies for any breach, or that the Company's trade secrets will 
not otherwise become known or independently discovered by its competitors.

                                      10

<PAGE>

It is possible that the Company's products or processes will infringe, or 
will be found to infringe, patents not owned or controlled by the Company, 
such as the patent owned by Connetics Corporation.  If any relevant claims of 
third-party patents are upheld as valid and enforceable, the Company could be 
prevented from practicing the subject matter claimed in such patents, or 
would be required to obtain licenses or redesign its products or processes to 
avoid infringement.  There can be no assurance that such licenses would be 
available at all or on terms commercially reasonable to the Company or that 
the Company could redesign its products or processes to avoid infringement.  
Litigation may be necessary to defend against claims of infringement, to 
enforce patents issued to the Company or to protect trade secrets.  Such 
litigation could result in substantial costs and diversion of management 
efforts regardless of the results of such litigation and an adverse result 
could subject the Company to significant liabilities to third parties, 
require disputed rights to be licensed or require the Company to cease using 
such technology.

LENGTHY APPROVAL PROCESS AND UNCERTAINTY OF GOVERNMENT REGULATORY 
REQUIREMENTS. Clinical testing, manufacture, promotion and sale of the 
Company's drug products are subject to extensive regulation by numerous 
governmental authorities in the United States, principally the FDA, and 
corresponding state and foreign regulatory agencies.  The Company believes 
that REMUNE and most of its other potential immune-based therapies will be 
regulated by the FDA as biological drug products under current regulations of 
the FDA.  Biological products must be shown to be safe, pure and potent 
(i.e., effective) and are subject to the same regulatory requirements as 
nonbiological products under the Food and Drug Administration Act, as amended 
by the FDA Modernization Act, except that a biological product licensed under 
the Public Health Services Act ("PHS Act") is not required to have an 
approved New Drug Application under the Federal Food, Drug and Cosmetic Act 
("FDC Act").  The FDA Modernization Act directed the FDA to take measures to 
minimize the differences in the review and approval of marketing applications 
for biological and nonbiological products.  The FDA Modernization Act also 
made significant revisions to the statutory requirements with regard to the 
approval of new biological and nonbiological products.  Among other things, 
the FDA Modernization Act established a new statutory program for the 
approval of fast track drugs, streamlined clinical research, and revised the 
content of product approval applications and the FDA review process.  The FDA 
is required to issue regulations and guidelines in order to implement certain 
of these new requirements.  Until the FDA implements these regulations and 
guidelines, it is impossible to predict the impact of the FDA Modernization 
Act on the review and approval of any marketing applications that the Company 
may submit to the FDA.  The FDC Act, the PHS Act and other federal and state 
statutes and regulations govern or influence the testing, manufacture, 
safety, effectiveness, labeling, storage, recordkeeping, approval, 
advertising, distribution and promotion of biological prescription drug 
products. Noncompliance with applicable requirements can result in, among 
other things, fines, injunctions, seizure of products, total or partial 
suspension of product marketing, failure of the government to grant premarket 
approval, withdrawal of marketing approvals and criminal prosecution.

The regulatory process for new therapeutic drug products, including the 
required preclinical studies and clinical testing, is lengthy and expensive 
and there can be no assurance that necessary FDA clearances will be obtained 
in a timely manner, if at all.  There can be no assurance as to the length of 
the clinical trial period or the number of patients the FDA will require to 
be enrolled in the clinical trials in order to establish the safety and 
efficacy of the Company's products.  The Company may encounter significant 
delays or excessive costs in its efforts to secure necessary approvals, and 
regulatory requirements are evolving and uncertain.  Future United States or 
foreign legislative or administrative acts could also prevent or delay 
regulatory approval of the Company's products.  There can be no assurance 
that the Company will be able to obtain the necessary approvals for clinical 
trials, manufacturing or marketing of any of its products under development.  
Even if commercial regulatory approvals are obtained, they may include 
significant limitations on the indicated uses for which a product may be 
marketed.  In addition, a marketed product is subject to continual FDA 
review.  Later discovery of previously unknown problems or failure to comply 
with the applicable regulatory requirements may result in restrictions on the 
marketing of a product or withdrawal of the product from the market, as well 
as possible civil or criminal sanctions.

The steps required before a biological drug product may be marketed in the 
United States generally include preclinical studies and the filing of an 
Investigational New Drug application with the FDA.  Reports of results of 
preclinical studies and clinical trials for biological drug products are 
submitted to the FDA in the form of a Biologics Licensing Application ("BLA") 
for approval for marketing and commercial shipment.  Submission of a BLA does 
not assure FDA approval for marketing.  The BLA review process may take a 

                                            11

<PAGE>

number of years to complete, although reviews of applications for treatments 
of AIDS, cancer and other life-threatening diseases may be accelerated or 
expedited. Failure of the Company to receive FDA marketing approval for 
REMUNE or any of its other products under development on a timely basis could 
have a material adverse effect on the Company's business, financial condition 
and results of operations.  In addition to obtaining approval for each 
biological drug product, an Establishment License Application usually must be 
filed and approved by the FDA.

Among the other requirements for BLA approval is the requirement that 
prospective manufacturers conform to the FDA's Good Manufacturing Practices 
("GMP") requirements specifically for biological drugs, as well as for other 
drugs. In complying with the FDA's GMP requirements, manufacturers must 
continue to expend time, money and effort in production, recordkeeping and 
quality control to assure that the product meets applicable specifications 
and other requirements.  Failure to comply with the FDA's drug GMP 
requirements subjects the manufacturer to possible FDA regulatory action.  
There can be no assurance that the Company or its contract manufacturers, if 
any, will be able to maintain compliance with the FDA's drug GMP requirements 
on a continuing basis.  Failure to maintain such compliance could have a 
material adverse effect on the Company's business, financial condition and 
results of operations.

The Company believes its proprietary GeneDrug and cancer treatment therapies 
will likely be regulated as biological products.  As with the Company's other 
potential products, the gene therapy and cancer products will be subject to 
extensive FDA regulation throughout the product development process, and 
there can be no assurance that any of these products will be successful at 
securing the requisite FDA marketing approval on a timely basis, if at all.

The FDA Modernization Act also amended the FDC Act to permit expanded access 
to individuals and larger groups to unapproved new therapeutic and diagnostic 
products.  Although the new law largely codifies existing FDA regulations in 
this area, it expands access to all investigational therapies under certain 
conditions.  Although the FDA has granted expanded access to REMUNE for those 
patients who are ineligible to enroll in the Phase III clinical endpoint 
trial, the FDA has to date not designated expanded access protocols for 
REMUNE as "treatment" protocols.  Either expanded access or a treatment 
protocol designation might permit third party reimbursement of some of the 
costs associated with making REMUNE available to patients in such an expanded 
access context.  There can be no assurance that the FDA will determine that 
REMUNE meets all of the FDA's criteria for use of an investigational drug for 
treatment use or that, even if the product is allowed for treatment use, that 
third party payers will provide reimbursement for any of the costs of 
treatment with REMUNE .

The FDA also has issued regulations to accelerate the approval of or to 
expedite the review of new biological drug products for serious or 
life-threatening illnesses that provide meaningful therapeutic benefit to 
patients over existing treatments.  Under the accelerated approval program, 
the FDA may grant marketing approval for a biological or nonbiological drug 
product earlier than would normally be the case.  In addition to the 
accelerated approval process, the FDA has established procedures designed to 
expedite the development, evaluation and marketing of new therapies intended 
to treat persons with life-threatening and severely-debilitating illnesses, 
especially when no satisfactory alternative therapy exists.  In addition, the 
FDA Modernization Act established a new statutory program for the approval of 
fast track drugs, including biological products.  There can be no assurance 
that the FDA will consider REMUNE or any other of the Company's products 
under development to be an appropriate candidate for accelerated approval, 
expedited review or fast track designation.

To market any drug products outside of the United States, the Company is also 
subject to numerous and varying foreign regulatory requirements, implemented 
by foreign health authorities, governing the design and conduct of human 
clinical trials and marketing approval.  The approval procedure varies among 
countries and can involve additional testing, and the time required to obtain 
approval may differ from that required to obtain FDA approval.  The foreign 
regulatory approval process includes all of the risks associated with 
obtaining FDA approval set forth above, and approval by the FDA does not 
ensure approval by the health authorities of any other country.  

TECHNOLOGICAL CHANGE AND COMPETITION.  The biotechnology industry continues 
to undergo rapid change and competition is intense in the fields of HIV, 
autoimmune disease, cancer and gene therapy, and such 

                                             12

<PAGE>

competition is expected to increase.  The Company will compete with fully 
integrated pharmaceutical companies, small biotechnology companies, 
universities and research organizations.  There can be no assurance that 
competitors have not or will not succeed in developing technologies and 
products that are more effective than any which have been or are being 
developed by the Company or which would render the Company's technology and 
products obsolete and noncompetitive.  Many of the Company's competitors have 
substantially greater experience, financial and technical resources and 
production, marketing and development capabilities than the Company.  
Accordingly, certain of the Company's competitors may succeed in obtaining 
regulatory approval for products more rapidly or effectively than the 
Company.  If the Company commences commercial sales of its products, it will 
also be competing with respect to manufacturing efficiency and sales and 
marketing capabilities, areas in which it currently has no experience.  There 
can be no assurance that competitors will not develop and commercialize more 
effective or affordable products.

DEPENDENCE ON THIRD PARTIES.  The Company's strategy for the research, 
development and commercialization of its products requires entering into 
various arrangements with corporate collaborators, licensors, licensees and 
others, and the Company's commercial success is dependent upon these outside 
parties performing their respective contractual responsibilities, including 
the analysis of the data generated in the Company's clinical trials.  The 
amount and timing of resources such third parties will devote to these 
activities may not be within the control of the Company.  There can be no 
assurance that such parties will perform their obligations as expected and 
the failure of third parties to perform their obligations would have a 
material adverse effect on the Company. Although the Company has 
collaborative agreements with several universities and research institutions, 
the Company's agreement with Bayer is the only collaborative agreement that 
provides the Company with contract revenue.  There can be no assurance that 
these collaborations will result in the development of any commercial 
products. Immune Response intends to seek additional collaborative 
arrangements to develop and commercialize certain of its products. There can 
be no assurance that the Company will be able to negotiate collaborative 
arrangements on favorable terms, or at all, in the future, or that its 
current or future collaborative arrangements will be successful.

LACK OF COMMERCIAL MANUFACTURING AND MARKETING EXPERIENCE.  The Company has a 
manufacturing facility for REMUNE located in King of Prussia, Pennsylvania, 
and a pilot manufacturing facility in Carlsbad, California for its other 
products. The Company has not yet manufactured its product candidates in 
commercial quantities.  No assurance can be given that the Company, on a 
timely basis, will be able to make the transition from manufacturing clinical 
trial quantities to commercial production quantities successfully or be able 
to arrange for contract manufacturing.  The Company believes it will be able 
to manufacture REMUNE for initial commercialization, if the product obtains 
FDA approval, but it has not yet demonstrated the capability to manufacture 
REMUNE in commercial quantities, or its autoimmune disease, cancer and gene 
therapy treatments in large-scale clinical or commercial quantities.  The 
Company has no experience in the sales, marketing and distribution of 
pharmaceutical products.  There can be no assurance that the Company will be 
able to establish sales, marketing and distribution capabilities or make 
arrangements with its collaborators, licensees or others to perform such 
activities or that such efforts will be successful. There can be no assurance 
of market acceptance of the Company's products, if they are developed and 
approved for commercialization.

The manufacture of the Company's products involves a number of steps and 
requires compliance with stringent quality control specifications imposed by 
the Company itself and by the FDA.  Moreover, the Company's products can only 
be manufactured in a facility that has undergone a satisfactory inspection by 
the FDA.  For these reasons, the Company would not be able quickly to replace 
its manufacturing capacity if it were unable to use its manufacturing 
facilities as a result of a fire, natural disaster (including an earthquake), 
equipment failure or other difficulty, or if such facilities are deemed not 
in compliance with the FDA's drug GMP requirements and the non-compliance 
could not be rapidly rectified.  The Company's inability or reduced capacity 
to manufacture its products would have a material adverse effect on the 
Company's business and results of operations.

The Company may enter into arrangements with contract manufacturing companies 
to expand its own production capacity in order to meet requirements for its 
products, or to attempt to improve manufacturing efficiency.  If the Company 
chooses to contract for manufacturing services and encounters delays or 
difficulties in establishing relationships with manufacturers to produce, 
package and distribute its finished 

                                       13

<PAGE>

products, clinical trials, market introduction and subsequent sales of such 
products would be adversely affected. Further, contract manufacturers must 
also operate in compliance with the FDA's drug GMP requirements; failure to 
do so could result in, among other things, the disruption of product 
supplies.  Until recently, biologic product licenses could not be held by any 
company unless it performed significant manufacturing operations.  The FDA 
recently amended its regulations in this regard, and the Company believes 
that under these new regulations it can now hold licenses for its biological 
products without performing significant manufacturing steps. Nonetheless, the 
Company's potential dependence upon third parties for the manufacture of its 
products may adversely affect the Company's profit margins and its ability to 
develop and deliver such products on a timely and competitive basis.

UNCERTAINTY OF PRODUCT PRICING, REIMBURSEMENT AND RELATED MATTERS.  The 
Company's ability to earn sufficient returns on its products will depend in 
part on the extent to which reimbursement for the costs of such products and 
related treatments will be available from government health administration 
authorities, private health coverage insurers, managed care organizations and 
other organizations.  Third party payors are increasingly challenging the 
price of medical products and services.  If purchasers or users of the 
Company's products are not able to obtain adequate reimbursement for the cost 
of using such products, they may forego or reduce such use.  Significant 
uncertainty exists as to the reimbursement status of newly approved health 
care products, and there can be no assurance that adequate third party 
coverage will be available. Failure to obtain appropriate reimbursement would 
have a material adverse effect on the Company.

VOLATILITY OF STOCK PRICE AND ABSENCE OF DIVIDENDS.  The market price of the 
Company's common stock, like that of the common stock of many other 
biopharmaceutical companies, has been and is likely to be highly volatile. 
Factors such as the results of preclinical studies and clinical trials by the 
Company, its collaborators or its competitors, other evidence of the safety 
or efficacy of products of the Company or its competitors, announcements of 
technological innovations or new products by the Company or its competitors, 
governmental regulatory actions, changes or announcements in reimbursement 
policies, developments with the Company's collaborators, developments 
concerning patent or other proprietary rights of the Company or its 
competitors (including litigation), concern as to the safety of the Company's 
products, period-to-period fluctuations in the Company's operating results, 
changes in estimates of the Company's performance by securities analysts, 
market conditions for biopharmaceutical stocks in general and other factors 
not within the control of the Company could have a significant adverse impact 
on the market price of the common stock.  The Company has never paid cash 
dividends on its common stock and does not anticipate paying any cash 
dividends in the foreseeable future.

                                          14

<PAGE>

PART II.  OTHER INFORMATION

ITEM 6. -- EXHIBITS AND REPORTS ON FORM 8-K

a)     Exhibits

          27.1    Financial Data Schedule

b)   Reports on Form 8-K

          Not applicable
                                          

                                          15

<PAGE>

                                          
                                     SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of 1934, the 
registrant has duly caused this report to be signed on its behalf by the 
undersigned thereunto duly authorized.


                                       THE IMMUNE RESPONSE CORPORATION



              5/8/98                   /s/ Charles J. Cashion
Date: ____________________________     ______________________________________
                                       Charles J. Cashion
                                       Sr. Vice President
                                       Secretary and Treasurer


                                        16